These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 29038654)

  • 41. TLR-9 signaling and TCR stimulation co-regulate CD8(+) T cell-associated PD-1 expression.
    Wong RM; Smith KA; Tam VL; Pagarigan RR; Meisenburg BL; Quach AM; Carrillo MA; Qiu Z; Bot AI
    Immunol Lett; 2009 Dec; 127(1):60-7. PubMed ID: 19751765
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Perforin-independent CD8(+) T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-alpha: relative insensitivity to Fas ligand.
    Liu AN; Mohammed AZ; Rice WR; Fiedeldey DT; Liebermann JS; Whitsett JA; Braciale TJ; Enelow RI
    Am J Respir Cell Mol Biol; 1999 May; 20(5):849-58. PubMed ID: 10226053
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells.
    Römmler F; Hammel M; Waldhuber A; Müller T; Jurk M; Uhlmann E; Wagner H; Vollmer J; Miethke T
    PLoS One; 2015; 10(2):e0116703. PubMed ID: 25695778
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth.
    Das M; Zhou X; Liu Y; Das A; Vincent BG; Li J; Liu R; Huang L
    Transl Oncol; 2020 Dec; 13(12):100856. PubMed ID: 32862105
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neoantigen Quality Predicts Immune Response, Survival.
    Cancer Discov; 2018 Jan; 8(1):6. PubMed ID: 29158230
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correction: Modeling the Specific CD4
    Flament H; Ramirez RA; Prémel V; Joncker NT; Jacquet A; Scholl S; Lantz O
    J Immunol; 2017 Aug; 199(4):1526. PubMed ID: 28784686
    [No Abstract]   [Full Text] [Related]  

  • 47. Erratum for the Research Article "A functional identification platform reveals frequent, spontaneous neoantigen-specific T cell responses in patients with cancer" by A. M. Miller
    Sci Transl Med; 2024 May; 16(746):eadp8153. PubMed ID: 38718137
    [No Abstract]   [Full Text] [Related]  

  • 48. Neoantigen-Targeting Vaccine Promotes T-Cell Response in Glioblastoma.
    Traylor JI; Satarasinghe P; Kuo JS
    Neurosurgery; 2019 Aug; 85(2):E207-E209. PubMed ID: 31304540
    [No Abstract]   [Full Text] [Related]  

  • 49. Correction to: NeoFox: annotating neoantigen candidates with neoantigen features.
    Bioinformatics; 2023 Dec; 39(12):. PubMed ID: 38140710
    [No Abstract]   [Full Text] [Related]  

  • 50. Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.
    Caushi JX; Zhang J; Ji Z; Vaghasia A; Zhang B; Hsiue EH; Mog BJ; Hou W; Justesen S; Blosser R; Tam A; Anagnostou V; Cottrell TR; Guo H; Chan HY; Singh D; Thapa S; Dykema AG; Burman P; Choudhury B; Aparicio L; Cheung LS; Lanis M; Belcaid Z; El Asmar M; Illei PB; Wang R; Meyers J; Schuebel K; Gupta A; Skaist A; Wheelan S; Naidoo J; Marrone KA; Brock M; Ha J; Bush EL; Park BJ; Bott M; Jones DR; Reuss JE; Velculescu VE; Chaft JE; Kinzler KW; Zhou S; Vogelstein B; Taube JM; Hellmann MD; Brahmer JR; Merghoub T; Forde PM; Yegnasubramanian S; Ji H; Pardoll DM; Smith KN
    Nature; 2021 Oct; 598(7881):E1. PubMed ID: 34608287
    [No Abstract]   [Full Text] [Related]  

  • 51. Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors.
    Pires ES; D'Souza RS; Needham MA; Herr AK; Jazaeri AA; Li H; Stoler MH; Anderson-Knapp KL; Thomas T; Mandal A; Gougeon A; Flickinger CJ; Bruns DE; Pollok BA; Herr JC
    Oncotarget; 2017 Feb; 8(9):16099. PubMed ID: 28403580
    [No Abstract]   [Full Text] [Related]  

  • 52. Neoantigen vaccine proven safe and immunogenic.
    Crunkhorn S
    Nat Rev Drug Discov; 2020 Dec; 19(12):838. PubMed ID: 33139898
    [No Abstract]   [Full Text] [Related]  

  • 53. Author Correction: Molecular mechanism of phosphopeptide neoantigen immunogenicity.
    Patskovsky Y; Natarajan A; Patskovska L; Nyovanie S; Joshi B; Morin B; Brittsan C; Huber O; Gordon S; Michelet X; Schmitzberger F; Stein RB; Findeis MA; Hurwitz A; Van Dijk M; Chantzoura E; Yague AS; Pollack Smith D; Buell JS; Underwood D; Krogsgaard M
    Nat Commun; 2023 Jul; 14(1):4522. PubMed ID: 37500629
    [No Abstract]   [Full Text] [Related]  

  • 54. Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy.
    Zhu G; Mei L; Vishwasrao HD; Jacobson O; Wang Z; Liu Y; Yung BC; Fu X; Jin A; Niu G; Wang Q; Zhang F; Shroff H; Chen X
    Nat Commun; 2017 Nov; 8(1):1482. PubMed ID: 29133898
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation.
    Seliktar-Ofir S; Merhavi-Shoham E; Itzhaki O; Yunger S; Markel G; Schachter J; Besser MJ
    Front Immunol; 2017; 8():1211. PubMed ID: 29067023
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improved Functionality of Exhausted Intrahepatic CXCR5+ CD8+ T Cells Contributes to Chronic Antigen Clearance Upon Immunomodulation.
    Kumashie KG; Cebula M; Hagedorn C; Kreppel F; Pils MC; Koch-Nolte F; Rissiek B; Wirth D
    Front Immunol; 2020; 11():592328. PubMed ID: 33613516
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mucosal Immunization with a pH-Responsive Nanoparticle Vaccine Induces Protective CD8
    Knight FC; Gilchuk P; Kumar A; Becker KW; Sevimli S; Jacobson ME; Suryadevara N; Wang-Bishop L; Boyd KL; Crowe JE; Joyce S; Wilson JT
    ACS Nano; 2019 Oct; 13(10):10939-10960. PubMed ID: 31553872
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CpG-ODN Facilitates Effective Intratracheal Immunization and Recall of Memory against Neoantigen-Expressing Alveolar Cells.
    Riehn M; Cebula M; Hauser H; Wirth D
    Front Immunol; 2017; 8():1201. PubMed ID: 29038654
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].
    Ren T; Cai YY; Liang YJ; Jin ML; Guo ZL; Tao MF; He X
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1168-72. PubMed ID: 18844109
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.
    Karan D; Krieg AM; Lubaroff DM
    Int J Cancer; 2007 Oct; 121(7):1520-8. PubMed ID: 17565748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.